Difference between revisions of "Team:Sheffield/episode9"
| Line 27: | Line 27: | ||
src="https://2016.igem.org/Template:Sheffield/scripts/backtotopbutton?action=raw&ctype=text/javascript"></script> | src="https://2016.igem.org/Template:Sheffield/scripts/backtotopbutton?action=raw&ctype=text/javascript"></script> | ||
<script | <script | ||
| − | src="https://2016.igem.org/Template:Sheffield/scripts/jquery-ui?action=raw&ctype=text/javascript"></script> | + | src="https://2016.igem.org/Template:Sheffield/scripts/jquery-ui?action=raw&ctype=text/javascript"></script> |
| + | <script | ||
| + | src="https://2016.igem.org/Template:Sheffield/scripts/popover?action=raw&ctype=text/javascript"> </script> | ||
<style type="text/css"> | <style type="text/css"> | ||
#top_title, #sideMenu{ | #top_title, #sideMenu{ | ||
| Line 276: | Line 278: | ||
<h2>Introducing our device to the market</h2> | <h2>Introducing our device to the market</h2> | ||
| − | <p>Misusing antibiotics and manufacturing a device incur costs. The costs of mass producing a device should be less than the costs involved in misusing antibiotics, for the device to have commercial viability in the real world. This could be modelled by taking into account the cost of materials and distribution of a device, and comparing this to the effect antibiotic resistance and misprescription has on a system such as the | + | <p>Misusing antibiotics and manufacturing a device incur costs. The costs of mass producing a device should be less than the costs involved in misusing antibiotics, for the device to have commercial viability in the real world. This could be modelled by taking into account the cost of materials and distribution of a device, and comparing this to the effect antibiotic resistance and misprescription has on a system such as the <button class="btn btn-lg btn-danger" data-placement="top" data-toggle="popover" title="National Health Service" data-content="The free health institutional service in Britain">NHS</button>.</p> |
| − | <p>If our device were to become a widespread diagnostic tool, it would require approval from regulatory authorities such as National Institute for Health and Care Excellence (NICE), the Medicines and Healthcare products Regulatory Agency (MHRA) and the International Organisation for Standardization (ISO). Further, we would need to wait for rulings from UK and EU government commissions concerning whether | + | <p>If our device were to become a widespread diagnostic tool, it would require approval from regulatory authorities such as National Institute for Health and Care Excellence (NICE), the Medicines and Healthcare products Regulatory Agency (MHRA) and the International Organisation for Standardization (ISO). Further, we would need to wait for rulings from UK and EU government commissions concerning whether <button class="btn btn-lg btn-danger" data-placement="top" data-toggle="popover" title="Genetically Modified" data-content="containing genetic material that has been artificially altered so as to produce a desired characteristic.">GM</button> live bacteria could be safely distributed within a healthcare setting.</p> |
<p>Public and private healthcare providers such as the National Health Service (NHS) and British United Provident Association (Bupa) should be consulted as these would be the end-users. We could further improve the device by conducting widespread trials in partnership with our end-users.</p> | <p>Public and private healthcare providers such as the National Health Service (NHS) and British United Provident Association (Bupa) should be consulted as these would be the end-users. We could further improve the device by conducting widespread trials in partnership with our end-users.</p> | ||
Latest revision as of 21:18, 19 October 2016
|
THE FUTURE |
|
|---|
Introducing our device to the market
Misusing antibiotics and manufacturing a device incur costs. The costs of mass producing a device should be less than the costs involved in misusing antibiotics, for the device to have commercial viability in the real world. This could be modelled by taking into account the cost of materials and distribution of a device, and comparing this to the effect antibiotic resistance and misprescription has on a system such as the .
If our device were to become a widespread diagnostic tool, it would require approval from regulatory authorities such as National Institute for Health and Care Excellence (NICE), the Medicines and Healthcare products Regulatory Agency (MHRA) and the International Organisation for Standardization (ISO). Further, we would need to wait for rulings from UK and EU government commissions concerning whether live bacteria could be safely distributed within a healthcare setting.
Public and private healthcare providers such as the National Health Service (NHS) and British United Provident Association (Bupa) should be consulted as these would be the end-users. We could further improve the device by conducting widespread trials in partnership with our end-users.
